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 Abstract  
 The availability of synthetic peptides has paved the way for their use in tailor-made interactions 
with biomolecules. In this study, a 16mer LacI-based peptide was used as an affinity ligand to 
examine the scale up feasibility for plasmid DNA purification. First, the peptide was designed and 
characterized for the affinity purification of lacO containing plasmid DNA, to be employed as a 
high affinity ligand for the potential capturing of plasmid DNA in a single unit operation. It was 
found there were no discernible interactions with a control plasmid that did not encode the lacO 
nucleotide sequence. The dissociation equilibrium constant of the binding between the 16mer 
peptide and target pUC19 was 5.0 ± 0.5 × 10-8 M as assessed by surface plasmon resonance. This 
selectivity and moderated affinity indicate that the 16mer is suitable for the adsorption and 
chromatographic purification of plasmid DNA. The suitability of this peptide was then evaluated 
using a chromatography system with the 16mer peptide immobilized to a customized monolith to 
purify plasmid DNA, obtaining preferential purification of supercoiled pUC19. The results 
demonstrate the applicability of peptide-monolith supports to scale up the purification process for 
plasmid DNA using designed ligands via a biomimetic approach. 
 
 1. Introduction 
 
The current high level of interest in structural biology information coupled with the growing 
demand for high purity DNA, employed as vaccines and gene therapies, has led to an interest in 
harnessing naturally occurring DNA affinity interactions for use in DNA purification and detection 
applications [1-9]. Furthermore, the stringent purity requirements of regulatory bodies (i.e. FDA, 
EMEA, TGA) [10] creates a demand for methods to obtain very pure bio-therapeutics or bio-
pharmaceuticals without contaminants. This demand is particularly strong for plasmid DNA 
(pDNA), which has potential in the bio-pharmaceutical industry for the expression of therapeutic 
proteins and peptides in vivo and as a vaccine [5]. 
 
The production of pDNA is often accomplished by lysis of the cells, followed by a 
clarification/concentration step and, finally, three or more chromatography steps [11-17] to remove 
host cell contaminants: RNA, proteins, endotoxins and genomic DNA (gDNA), which may 
constitute as much as 98% of material by dry weight. Affinity chromatography can be used to 
specifically capture target product (pDNA) and isolate it based on specific biological function or 
individual chemical structure, thus having the power to reduce downstream processing when the 
selectivity and binding strength of optimised affinity ligands enable an otherwise multi-step 
purification procedure to be replaced by a single affinity purification step. However, no affinity 
purification protocol can be utilised without suitable ligands [18], and this is especially important to 
meet with the demands and rigours of industry requirements.  
 
 Several ligands for affinity purification of pDNA have been investigated at the laboratory scale. The 
formation of triple helices between oligonucleotides attached to a chromatographic matrix and 
duplex sequences (present on the plasmid) has been used to purify pDNA [19, 20]. In these reports, 
more than 60% recovery yields were reached and the RNA and gDNA content were reduced 
significantly, but slow binding kinetics were displayed creating a limitation at scale [19, 20]. 
Studies using proteins as affinity ligands to purify pDNA have also been described such as a zinc 
finger DNA-binding protein [21] and Lac repressor protein [22, 23]. Although effective, there is a 
limitation of scale and economics as such ligands are large and often challenging to purify. 
 
Despite these limitations, the application of the Lac repressor protein in displacement 
chromatography was shown to retain biological activity after immobilization [24]. Hasche and Voß 
(2005) found that interaction between repressor molecules in the form of a short operator sequence 
was specific for double stranded DNA, with no RNA interactions being detected [25]. The Lac 
repressor (lacI) is a DNA binding protein that regulates expression of the lac operon. LacI has been 
studied extensively at the genetic and structural level [26-33]. From the structure of the protein and 
DNA complex (Figures 1 and 2, the Protein Database entry the code 1JWL), the DNA binding 
domain consists of helix I (residues 7 to 13), a turn, helix II (17 to 26), helix III (33 to 47), and the 
hinge helix IV (50 to 59). Within LacI, this domain binds to DNA that is formed through 
association of the ~300 amino acid residue at C-terminal domain. The binding is a complex 
interaction of hydrophobic interactions and hydrogen bonding [26]. 
 
Because of the well-characterised and favourable properties, LacI-based approaches have also been 
described for affinity adsorption of pDNA, however the yield of pDNA was low [22, 23, 34]. One 
contributing factor was the strong binding between pDNA and ligands. Ideally, the binding should 
 be strong enough to avoid leakage during the pDNA application and wash phases, whilst enabling 
complete release of pDNA during the elution phase. The optimal dissociation constant for an 
affinity binding mechanism for use in a chromatographic system lies in the approximate range of 
10–6 - 10–8 M and is the range for many affinity chromatography systems (e.g. maltodextrin-maltose 
binding protein (10-7 M), Calmodulin chromatography (10-8 M)) and is the target range for 
engineered systems where native binding affinities are too high for elution (e.g. Softlink™ avidin 
(10-7 M), Strep-Tactin® superflow (10-6 M)). This range allows designed peptides to rapidly bind 
with suitable affinity for pDNA, selectivity of the target pDNA without the co-purification of other 
biomolecules (gDNA, RNA, protein, and endotoxins), and tight binding sufficient for process 
rigours but appropriate for elution from the matrix.  
 
For this purpose, the naturally occurring binding of lacO/LacI was optimized for purification of 
pDNA. As previously reported, synthetic peptides based on the Lac repressor protein (lacI) strongly 
bind pDNA containing lacO sequences [5]. In order to obtain lacO-binding peptides that bind with 
suitable affinity, we reasoned that deletion of some non-contributing amino acids could create a 
peptide that retains the DNA binding properties of the Lac repressor.  
 
The sequence chosen for the 16mer peptide utilizes a portion of the helix II DNA binding domain of 
the Lac repressor (-TVSRVVNQ-) as reported from the crystal structure (Bell and Lewis 2001). N-
terminal to this fragment is a designed sequence (NH-CMKYVSHG-) which is predicted to provide 
a coil-like secondary structure to this region of the peptide, supportive of the natural helicity of the 
DNA binding domain (Fig. 1 and 2), while also providing a spacer from chromatography matrices. 
The cysteine residue is important for attachment to biosensor and chromatographic supports and 
provides known chemical manipulation such as coupling or heterobiofunctional modification.  
  
The designed portion also imparts favourable chromatography-relevant physicochemical properties 
for the entire 16mer peptide [35] relevant to scaled use in chromatography such as economics and 
regeneration; the molecular weight is low (mw 1808.1 amu) being economical to manufacture, the 
pI is not excessively high (pI 9.31) as often seen for DNA binding entities which can be problematic 
for chemical attachment or behaviour on supports. The aliphatic index contributed by the relative 
volumes of the four valine residues is reasonably high (72.5%) which is regarded as a positive 
factor for thermostability and refolding [35, 36], and the grand average of hydropathicity (GRAVY), 
which is a hydropathic summation of all residues, indicates a soluble peptide (-0.087) [37]. These 
facets favour the refolding of the peptide, which may include harsh regeneration conditions without 
collapse or precipitation on the surface of the column. 
 
This study tested the utility of the designed 16mer peptide as an affinity ligand immobilized on a 
customized monolith to purify pUC19 pDNA containing a lacO nucleotide sequence. In an 
engineering context, the potential of process scale up is always one of primary concern. High-
density bacterial lysates produced from bioreactors are very viscous and the desired pDNA are large 
molecules, causing significant process complexities at scale. The purification of large 
polynucleotides such as pDNA is hampered by the performance of conventional particulate 
chromatographic supports. Most of these particulate supports are made for small molecules and 
proteins, typically targeting molecules with diameter less than 10 nm [38]. In columns packed with 
such supports, large molecules such as pDNA with a size of 100 nm to over 300 nm in diameter 
adsorb predominantly at the beads outer surface [39]. Thus, the pore characteristics of 
chromatographic supports need to be considered for applications where the target molecules are 
several orders of magnitude larger than standard molecules typically applied to the columns. The 
 large pores of monoliths will allow penetration of large pDNA molecules to the internal surface 
area at high flow rate with low pressure drops [40-45]. Polymethacrylate monolithic supports are 
optimal adsorbents for large biomolecule separation. These adsorbents have large pore diameters 
and can be easily modified by functionalising with affinity ligand [15-17, 20, 46, 47]. Monolithic 
systems are particularly attractive for pDNA purification; the surface characteristics are inert to the 
target pDNA molecule and many contaminants, it is simple to tailor monolithic pore sizes (through 
alteration in synthesis conditions) and naturally the scalability favours industrial processes [47].  
We therefore sought to test the modified lacI based 16mer peptide for affinity pDNA purification 
using peptide-monolith constructs, which included the synthesis and engineering of poly(glycidyl 
methacrylate–co–ethylene glycol dimethacrylate) monoliths. The ultimate goal of this study is to 
assess the applicability of peptide-monoliths for the scale up of pDNA purification processes. 
 
2. Material and Methods 
 
2.1. Material/Instruments 
 
N-hydroxysuccinmide (NHS), N-ethyl-N’ – (3- diethlamino propyl) carbodiimide hydrochloride 
(EDC), sensor chip C1 (research grade) and HBS-EP buffer pH 7.4 were purchased from GE 
Healthcare (Biacore, Sweden); Agarose (Promega), freezer (Nuaire), centrifuge (Heraeus), Wizard 
Maxipreps DNA Purification System (Promega), electrophoresis gel analyser (Bio-rad) and 
spectrophotometer (Shimadzu), Ethylene glycol dimethacrylate (EDMA), glycidyl methacrylate 
(GMA), ethylenediaminetetraacetic acid (EDTA), sodium chloride, sodium hydroxide, ethidium 
bromide and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and of analytical 
grade if not stated otherwise. 
  
2.2. Plasmid DNA and cultivations of bacteria 
 
Plasmid pUC19 (0.01 g/l) purchased from Invitrogen was transformed and propagated in E. coli 
DH5 (EndA- from Invitrogen) in a 17 L fermentor (Bioflow 410, New Brunswick Scientific, USA).  
A culture of E. coli DH5 was grown in LB medium supplemented with 100 g/ml ampicillin 
(Austrapen) and was incubated overnight at 37 °C. Unused cells were refrozen in a dry ice/ethanol 
bath for 5 minutes before returning to the -75 °C freezer (Nuaire, ultralow freezer, Japan). 
 
DH5α is an E.coli strain B derivative and has the genotype: F– 80lacZM15 (lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 – thi-1 gyrA96 relA1. Therefore, DH5α 
has the normal and fully functional genomic lac operon of E. coli. The lambdoid prophage 
(80lacZM15 (lacZYA-argF) U169) is a defective phage carrying the lacZM15 deletion (as 
well as wild-type lacI, lacYA, and flanking sequences). As such, DH5α has additional lac operon 
genes present as part of the blue-white screening phenotype, including lacI.  
 
On a technical note: some strains of DNA-propagating E.coli phenotypically over-express lacI. 
Specifically strains that contain lacIq/lacIQ and lacIQ1 have a phenotype for overproduction of lacI 
governed by mutations in the upstream promoter site (-35 GCGCAA to GTGCAA or a 15 bp 
deletion respectively), creating an optimal promoter upstream of lacI and leading to constitutive 
expression. However, similar to DH5α used here, this is subject to growth and process conditions 
and can be optimized and controlled just like any other process parameter. I.e. preparation of lysates 
in preceding unit operations prior to chromatography using conditions that dissociate protein-DNA 
complexes or manipulation of standard lac operon conditions by controlled media and reactor 
 conditions (e.g. cAMP levels, CAP protein concentrations, lactose presence/absence, glucose 
presence/absence and IPTG presence/absence). 
 
2.3. Isolation of pDNA and spectroscopy 
 
Control Plasmid pEGFP-N1 and assay pUC19 were produced via the use of the Promega Wizard™ 
Plus Maxiprep DNA purification System (Promega, USA) with purification protocols for high copy 
number vectors according to the instructions of the manufacturer. Cell culture (250 ml) was used for 
pDNA purification each time. The purified pDNA was used to characterise the interaction of the 
designed 16mer peptide with DNA. TE buffer (10 mM Tris-HCl, 1 mM EDTA), pH 8.0 was used in 
DNA ladder dilutions. DNA concentrations were determined using UV spectroscopy at 260nm 
(A260).  All sample used had an initial A260 /A280 ration between 1.7 and 1.9.  
 
2.4. pEGFP-N1 
 
In order to investigate the binding specificity of the lac operon (lacO) sequence contained in the 
pDNA and its repressor, the lacI protein, another plasmid DNA that does not contain the lacO 
sequence used in this research was pEGFP-N1 (Clontech laboratories, CA, USA), a 4733 kb 
plasmid encoding an enhanced green fluorescence protein. Plasmid pEGFP-N1 was purified from 
JM109 E-coli cells. The molecular weight of pEGFP-N1 was 2.924 × 106 g/mol.  
 
The plasmid pEGFP-N1 was selected to conduct a control experiment with the 16mer peptide. From 
comparison of the restriction map and multiple cloning sites (MCS) of pEGFP-N1 and pUC19 
vectors, all restriction sites used in this study are unique 
 (http://www.pkclab.org/PKC/vector/pEFGPN1.pdf).  Its backbone provides a pUC origin of 
replication for propagation in E. coli. However, the alignment results from the Matcher program 
(http://www.ba.itb.cnr.it/BIG/PatSearch/) confirm that there is no identical sequence of lacO1 and 
lacO3 in pEGFP-N1 or in pUC19 and similar segment sequences of DNA are not homologous to the 
important region where lacI helix II binds.      
 
2.5. Gel electrophoresis 
 
The integrity of pDNA and change in the proportion of isoforms was assessed by gel 
electrophoresis. 0.8 % agarose gels were used with a 1kb DNA ladder (Promega, USA) as a marker 
with fragments of 10, 8, 6, 5, 4, 3, 2, 1.5, 1 and 0.5kbp. Every sample (350 µg DNA loaded) was 
loaded as indicated in the results section onto the 0.8% agarose gel containing 0.05 g/ml ethidium 
bromide and electrophoresised at 66 V for 90 mins in TAE (Tris-acetate electrophoresis buffer (10 
mM Tris, 10 mM acetate acid, 1 mM EDTA)). All the gels were scanned and analysed using 
Quantity OneTM gel documentation and densitometric system (Bio-rad laboratories Inc., CA, USA).  
 
2.6. Restriction endonuclease digestion of purified pDNA 
 
Plasmid DNA (pUC19) was treated with EcoRI. Following digestion, the various forms of pUC19 
DNA was separated by agarose gel electrophoresis in the presence of ethidium bromide. The gel 
was visualized under UV light and the image recorded for later interpretation.  
 
2.7. LacI Peptide 
 
 The 16mer peptide was custom synthesized under contract by Mimotopes Pty Ltd. (Melbourne, 
Australia). This 16 amino acid residue oligopeptide (NH-CMKYVSHGTVSRVVNQ-COOH), 
comprises a DNA-binding domain of Helix II from the LacI protein -TVSRVVNQ-. The peptide 
sequence and secondary structure prediction appears in Fig. 1 and its schematic presentation within 
the lacI protein is shown in Fig. 2 based on the protein database entry 1JWL, which demonstrates 
the helical nature of the lacI protein and feasibility of utilising Helix II due to the extensive bonding 
and deep penetration of the peptide that is expected based on this high-resolution crystal structure. 
 
 
2.8. Surface plasmon resonance analysis 
 
Surface Plasmid Resonance (SPR) assays were performed as previously described [48]. Biacore X 
and C1 sensor chip were both supplied by GE Healthcare (Biacore - Uppsala, Sweden). Biacore 
experiments were performed with Hepes-buffered saline (HBS pH 7.4) as a running buffer (0.01 M 
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20, sterile-filtered and degassed). 
The pDNA binding was monitored using a flow rate of 30µl/min and the sensor chip surface was 
regenerated after each experiment by several injections of 30µl of 1 M NaCl (pH 10). The principle 
and application of the system employing the method of SPR detection is well described [49]. 
Coupling of the 16mer peptide to the sensor chip C1 utilised the N-terminal cysteine and the ligand 
thiol method as described [48, 50]. 
 
The immobilisation of peptide was performed using 90µl of PDEA in borate buffer pH8.3 on the 
carboxymethalyted matrix activated with 50µl of a mixture of 0.2 M EDC and 0.05 M NHS. Then, 
90µl of the peptide (200µg/ml in Formate buffer, pH 4.3) was applied to flow cell No. 2 of each 
 sensor chip C1. Flow cell No.1 was kept free of peptide solution and acted as reference cell in the 
test procedure. After immobilization both sensor chips were blocked by serial injection of L-
cysteine (20µl of 50mM) onto both flow cells. The immobilization procedure of the 16mer peptide 
is provided in Fig. 3.  
 
2.9. Binding of dsDNA to immobilized LacI peptide 
 
The control dsDNA purified using the plasmid mini-prep kit was diluted with HBS buffer, pH 7.4. 
Serial dilutions of the pDNA were loaded onto the Biacore C1 chip. Based on the SPR principle, 
when molecules in the sample bind to the sensor surface, the concentration and therefore the 
refractive index at the surface changes and a SPR response is detected. All biosensor data was 
studied using steady-state affinity analysis using BIAevaluation software (version 4.1 - Biacore, 
Uppsala Sweden).  
 
Analysis was conducted assuming a Langmuir (1:1 model), where one analyte interacts with one 
ligand to form a complex on the surface. In biosensor terms, the free species is described as the 
analyte “A” and is pDNA in these experiments. The immobilised ligand (the 16mer lacI peptide) on 
the sensor surface is described as species “B” that subsequently interact to form the combined “AB” 
complex.  
 
The maximum binding capacity (Rmax) where 100% of all the immobilised ligand B is saturated 
with the analyte A to form the AB complex was calculated as follows:  
 
Rmax (RU) =  analyte mw    x immobilisation level (RU) x stoichiometry 
                ligand mw 
 
The steady-state approximation was then made by plotting Req vs concentration, where Req is the 
steady state level at a given conventration value. The equilibrium dissociation constant (KD) was 
then determined as Rmax/2 as shown in figure 5 using the plateau regions of the sensorgrams.  
 
2.10. Synthesis of monolith and immobilization of peptide  
 
Synthesis of monolith and immobilization of peptide assays were performed as previously described 
[51]. Free radical liquid porogenic co-polymerisation of ethylene glycol dimethacrylate (EDMA) 
and glycidyl methacrylate (GMA) was used to prepare the monolith support. The cyclohexanol/1-
dodecanol was added into EDMA/GMA mixture as an alcohol-based bi-porogen solvent in the 
proportion of 50/10/20/20 (cyclohexanol/1-dodecanol/GMA/EDMA) in a total volume of 4 ml 
mixture. AIBN (1% weight with respect to monomer) was used to initiate the polymerisation 
process. The polymer mixture was sonicated for 10 min and sparged with N2 gas to expel dissolved 
O2. 4 ml of the mixture was gently transferred into a 12 cm × 1.5 cm polypropylene column (Biorad) 
and sealed before placing in a water bath (18 h, 50 °C). The polymer was washed to remove all 
porogens and other soluble materials with methanol. The polymer was washed again with 0.5 M 
Na2CO3, 1.0 M NaCl, pH 11.5 followed by 50 g/ml solution of 16mer peptide in binding buffer 
(0.1 M Tris-HCl, pH 7.5, 0.5 M NaCl, 1 mM EDTA) and the reaction was allowed to proceed (10 h, 
4˚C). The resulting resin was washed with Milli-Q water. The ligand density was found to be 
0.03µg 16mer peptide/ml monolith by measuring the concentration of peptide in binding buffer 
before and after immobilization. 
 
 2.11. Packed Bed Chromatography 
  
A 12 cm × 1.5 cm polypropylene column (Biorad) was packed (during the synthesis of methacrylate 
monolith) with 4 ml of monolith and equilibrated with ten column volumes of PBS buffer. Feed 
containing the pUC19 pDNA in PBS (100.2µg, 0.2ml) was loaded onto the column at a rate of 0.5 
ml/min. The column was then washed with 5 column volumes of PBS buffer and the pUC19 pDNA 
was eluted with PBS buffer with additional 1M NaCl at an increased flow rate of 1ml/min. The 
column was operated using Duoflow biological chromatographic system (Biorad, USA), with no 
pressure changes noted under flow conditions of 0.2, 0.5 and 1ml/min. All fractions were analyzed 
by 0.8 % agarose electrophoresis and Picogreen Assay. 
 
2.12. Column cleaning and regeneration procedure 
 
The functionalized monolith column was cleaned with a solution containing 0.1 M NaOH, 1 M 
NaCl and 10% EtOH followed by 10% EtOH only. The column was then regenerated with 25 mM 
Tris–HCl, 2.0 M NaCl, pH 8.1 and equilibration was performed with the appropriate starting buffer 
until a steady UV baseline was obtained. 
 
2.13. Dynamic binding capacity for pDNA 
 
A polypropylene column (Biorad, USA) was connected to a Duoflow biological chromatographic 
unit (Biorad, USA) via an adaptor, and used for determination of pDNA dynamic binding capacity. 
These experiments were conducted at a flow rate 0.2 ml/min at room temperature and pDNA 
concentrations 69.9 µg/ml. The column was equilibrated with 0.01 M PBS buffer, pH 7.4.  
Recording breakthrough curves and calculating the amount of bound pDNA per ml support at 50% 
 breakthrough provided dynamic binding capacity values by subtracting the value obtained under 
non-binding conditions. The column was cleaned and regenerated with a 0.1 M NaOH solution.  
 
3. Results and discussion 
 
3.1. Binding of pUC19 pDNA to the 16mer peptide monitored by SPR 
 
In previous work, a 186 bp dsDNA fragment of pUC19 template and a 64mer peptide ligand 
containing the complete LacI DNA binding domain (helix I - helix IV) was studied [52]. The 
feasibility study using the 64mer peptide ligand for pDNA purification was positive, however the 
yield was low owing to the strong affinity between 64mer peptide and pDNA being of the order of a 
dissociation constant of 5.7 x 10-11 M [23, 34]. We reasoned that deletion of some non-contributing 
amino acids could create a peptide that would retain the DNA binding properties of the Lac 
repressor.  
 
A 16mer peptide was then designed to mimic helix II binding in the Lac repressor protein. We have 
previously described the kinetics of the 16mer peptide compared to the 64mer (Helix I to IV), 
47mer (Helix I to III), 27mer (Helix I to II) and the designed 16mer (portion of Helix II) [48]. Here 
we fully described the properties of the 16mer peptide and its behavior during chromatographic 
purification of target pDNA. Fig.1 shows the amino acid sequence of the potential DNA-binding 
synthetic peptide 16mer, corresponding to residues 19-26 of the DNA binding domain of LacI 
protein [33]. The 16mer peptide was immobilized to a BIAcore sensor chip using a thiol coupling 
reagent PDEA as shown in Fig. 3.  
 
 Plasmid pUC19 was applied to the 16mer peptide immobilized on the sensor chip surface and the 
interaction was monitored in real-time by surface plasmon resonance- based BIAcore system. 
Plotting the response (RU) against time (seconds) during the course of an interaction provides a 
quantitative measure of the progress of the interaction. A typical sensorgram is shown in Fig. 4, 
indicating the binding of pUC19 to immobilized LacI peptide. Between each run, the chip surface 
was regenerated using 1 M NaCl, pH 10.   
 
Figure 4 presents the comparison of subtracted sensorgram obtained after the injections of a series 
of pUC19 concentration over the 16mer peptide surface and blank surface with a 600.1 g/ml 
control plasmid pEGFP-N1. As shown in Fig. 4, the increase in response units was observed after 
pUC19 loading following subtraction of the blank flowcell 1. A surface response to the 16mer 
peptide was observed with pUC19 (19.2 RU at 0.05 g/ml pUC19) while no difference was 
observed after injection of plasmid pEGFP-N1 at a high concentration (600.1 g/ml). This indicates 
that 16mer peptide specifically interacted with pUC19 since it had no binding to plasmid pEGFP-
N1 which did not contain lacO region.  
 
As shown in the sensorgram (Fig. 4), pUC19 had a very rapid on-rate that is characteristic of 
protein- or peptide-DNA associations and often ascribed to conformational changes within the DNA 
or protein/peptide upon interaction. Such kinetic events may involve non-specific electrostatic 
associations (e.g. with the phosphate backbone) prior to specific sequence interactions with the 
pUC19 operator sequence as suggested [53].  
 
The adsorption isotherm (Fig. 5) is Langmuir in nature [48], implying a strong 1:1 interaction 
between pUC19 molecules and the 16mer peptide immobilized on the sensor chip.  The isotherm 
 has a sharp initial rise, suggesting a high affinity between pUC19 molecules and the 16mer peptide. 
In addition, the dissociation constant of the binding (shown as Rmax/2 in Fig. 5) between 16mer 
peptide and pUC19 was 5.0 ± 0.5×10-8 M, which indicates that it has an optimum affinity for pDNA 
purification, which is ideally within the range of 10-8 and 10-6 M and this could be tested in the 
chromatographic system. 
 
3.2. Effect of different buffer on the binding between pDNA and peptide 
 
As shown in Table 1, the different standard DNA buffers (all at 7.4), with varied ionic strength, 
have some effect on the binding between pDNA and 16mer peptide. The 16mer - pUC19 interaction 
had the strong affinity (3.0 ± 0.3 ×10-9 M, I=110 mM) in a lower ionic strength Tris.HCl buffer 
(100 mM NaCl), followed by HBS buffer (5.0 ± 0.5 ×10-8 M, I=150 mM), with the weakest affinity 
in PBS buffer (6.5 ± 0.3 ×10-8  M, I=161 mM). However, these values are all within a reasonable 
and close range and from these indications the weaker affinity of the PBS buffer was selected as 
suitable for the chromatography work.   
 
3.3. Packed bed adsorption of pure pUC19 to the 16mer peptide 
 
Purified pUC19 (100.2 g, 0.2 ml) was loaded onto the 4 ml monolith column immobilized with the 
16mer peptide at a flow rate of 0.5 ml/min, followed by a washing step with 0.01 M PBS buffer, pH 
7.4. The subsequent elution of bound pDNA used a higher salt phosphate buffer (0.01 M phosphate, 
2 M NaCl) and a faster flow rate of 1.0 ml/min.  The OD260nm and buffer B signal from the Duoflow 
biological chromatography are plotted against elution time in Figure 6, showing that there was only 
 a single product peak during the prolonged elution phase. This indicates that the 16mer peptide had 
sufficient affinity to capture the pUC19 DNA under chromatography rigors.  
 
An ethidium bromide agarose electrophoresis gel (Fig.7) shows that the single eluted pUC19 
product forms a discrete DNA band with no signs of degradation or breakdown products.  
Densitometry analysis of the gel bands shows the eluted fraction comprises 96% supercoiled pDNA. 
This indicates that the 16mer peptide has shown preference for adsorption of the supercoiled pDNA 
over linear and open circular forms of pDNA (Inset image of Fig. 6). The eluted pDNA (lane 2 in 
Fig. 7) was only in supercoiled form. As  can be seen in lane 1 in Fig. 7, endonuclease digestion gel 
of the purified pDNA shows that an EcoRI cut supercoiled pDNA into a relaxed linear form, 
migrating differently to the expected supercoiled pDNA (ca. 3kbp cf ca. 1.8kbp) using the digestion 
method [54].  
 
3.4 Dynamic binding capacity of pDNA 
 
Breakthrough curves provide information on the dynamic binding capacity of a separation medium. 
The pDNA solution was pumped through the monolithic column at a defined flow rate, and the 
absorbency of the outlet at 260 nm was measured.  A breakthrough curve is shown in Fig.8 and 
dynamic binding capacity was extracted manually by determination of the volume corresponding to 
50% breakthrough. Multiplication of this volume by the initial feed concentration gives the dynamic 
binding capacity. At 50% breakthrough the binding capacity was found to be 0.39 mg pDNA/ml 
monolith immobilized with the 16mer peptide. This is lower than for anion exchange monolith 
(about 6.0 mg/ml). However, it should be highlighted that anionic media has only a moderate level 
of active discrimination between RNA, gDNA and other contaminating cellular debris, and cannot 
 readily discriminate two distinct pDNA species as demonstrated with the 16mer and the pEGFP-N1 
control plasmid. Furthermore, neither polymerization nor immobilization conditions for peptide 
capture were optimized for maximal yield, which could greatly increase the capacity for scaled 
purification. Hence the presented data indicate that the 16mer peptide immobilized monolith can be 
employed as a novel stationary phase for low contaminant chromatographic purification of pDNA 
and further studies will investigate possible advantages over the existing chromatographic supports, 
especially beyond the laboratory scale. 
 
4. Conclusions 
 
The specific capture of pDNA was achieved using a new type of affinity ligand – the 16mer LacI-
based peptide. This study enables a novel approach to address pDNA purification problems using 
the DNA binding properties of LacI. Initially peptide-DNA affinities were examined using a surface 
Plasmon resonance Biacore system before peptide immobilisation onto a monolith support.  In the 
case of designed peptides, we were able to control the orientation of the ligand to its target molecule 
in the Biacore system. The dissociation constant of the binding between the 16mer peptide and 
pDNA is 5.0 ± 0.5 ×10-8 M, indicating that the 16mer peptide potently binds pDNA within an 
optimum dissociation constant for process rigors (within the range of 10-8 – 10-6 M). This was also 
confirmed using pUC19 applied on a customized monolith chromatography support functionalised 
with the 16mer peptide. There was only one product peak appearing in the extended elution phase, 
comprising highly pure supercoiled pDNA from the single chromatographic unit operation. The 
agarose gel of the fraction confirmed the peak was pDNA and endonulease digest showed that it 
was supercoiled pDNA. The results imply that supercoiled pDNA was preferentially captured in a 
single chromatographic unit step. Therefore, this biomimetic approach utilising only a portion of the 
 LacI protein as a designed ligand to purify pDNA is presented as a suitable alternative for pDNA 
purification. 
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Table 1 Effect of binding buffers on the kinetics of the interaction of peptides designed - plasmid 
DNA 
 
 
Figure legends: 
 
Figure 1. Structure of the designed 16mer peptide. Termini: H-    -OH. The peptide comprises an 
N-terminal cysteine for chemical manipulation in the designer sequence and a C-terminal fragment 
from helix II of the Lac repressor. Secondary structure was predicted using the Advanced Protein 
Secondary Structure Prediction Server (APSSP) (http://imtech.res.in/raghava/apssp/) employing a 
nearest neighbor and neural network approach [55]. The nomenclature is in Table (H = helix; E = 
Strand; C = Coil) and probability of correct assignment shown. 
 
Figure 2. The N-terminal DNA binding domain (residues 1–60) of LacI is shown with helix II 
present in red binding to the minor groove of the lacO sequence (protein data base: 1JWL is the 
code for the structure of the protein and DNA complex). Figure generated using Molsoft ICM 
Browser (version 3.4-8f, MolSoft L.L.C.). A large contribution of bonding can be seen with the 
helix, which penetrates the major DNA binding groove. 
 
Figure 3. Sensorgram of immobilisation of 16mer peptide by thiol ligand method. Four stages in 
the immobilization procedure were indicated: NHS/EDC, activation of sensor chip by NHS/EDC; 
PDEA, modification by PDEA; Ligand, immobilization of ligand (16mer peptide); L-cysteine, 
deactivation and washing with 50 mM L-cysteine and 1 M NaCl.  R indicates the amount of 
ligand immobilized. 
 
Figure 4. Comparison of subtracted sensorgram obtained after the injections of a series of pUC19 
concentration over the 16mer peptide surface and blank surface with a 600.1 g/ml  control plasmid 
 pEGFP-N1. The increase in response unit was observed after pUC19 loading while no change with 
pEGFP – N1 loading. 
 
Figure 5. Adsorption isotherm for plasmid pUC19 binding to 16mer peptide immobilized to a 
Biacore C1 chip measured in response units. The C1 chip was equilibrated before each run with 
HBS buffer pH7.4 and regenerated after each run. The amount of bound plasmid DNA was 
estimated by monitoring the surface plasmon resonance signal (RU) at a fixed time just before the 
end of injection. Rmax/2 = KD, So the dissociation constant of the binding between pDNA and 16mer 
peptide was 0.5 × 10–7 M = 5 × 10–8 M. 
 
Figure 6. Chromatogram of plasmid pUC19 loaded on 16mer peptide immobilised on self-made 
monolith. Bound plasmid DNA was eluted using PBS buffer (0.01 M PBS, KCl 0.0027M; pH7.4) 
with additional NaCl (final concentration: 1M). Inset image: 0.8 % Ethidium Bromide agarose 
electrophoresis gel of purified plasmid DNA.  Lane 1: pDNA sample 5µl, lane M: 5µl 25µg/ml 
1kbp DNA ladder. The clear apparent band is supercoiled (SC) pDNA. 
 
Figure 7a. Agarose electrophoresis gel of plasmid DNA with 16mer peptide immobilised on a 4 ml 
customized monolith (negative agarose gel). M: 1kb DNA marker; lanes 1 and 2: eluted pDNA; 
Figure 7b. Restriction endonuclease digestion of purified pDNA. EcoRI cut supercoiled pDNA into 
linear pDNA (ca. 3kbp) using the method described before [54]. 
 
Figure 8. Breakthrough curve of pDNA using 16mer peptide – monolith chromatography.69.9 
µg/ml of plasmid in 0.01M PBS buffer was loaded in the breakthrough experiment. 
No Helix I, Turn, Loop or Helix III 
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Figure 1. Structure of designed 16mer peptide. Termini: H-    -OH. The peptide 
comprises an N-terminal cysteine for chemical manipulation in the designer sequence 
and a C-terminal fragment from helix II of the lac repressor. Secondary structure was 
predicted using the Advanced Protein Secondary Structure Prediction Server (APSSP) 
(http://imtech.res.in/raghava/apssp/) employing a nearest neighbor and neural network 
approach [55]. The nomenclature is in CASP format (H = helix; E = Strand; C = Coil) 
and probability of correct assignment shown. 
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Figure 2.  The N-terminal DNA binding domain (residues 1–60) of LacI is shown 
with helix II present in red binding to the minor groove of the LacO sequence (pdb 
1JWL). Figure generated using Molsoft ICM Browser (version 3.4-8f, MolSoft 
L.L.C.). 
  
 
 
 
 
 
 
 
 
 
Figure 3. A sensorgram of immobilisation of 16mer peptide by thiol ligand method. 
Four stages in the immobilization procedure were indicated: NHS/EDC, activation of 
sensor chip by NHS/EDC; PDEA, modification by PDEA; Ligand, immobilization of 
ligand (16mer peptide); L-cysteine, deactivation and washing with 50 mM L-cysteine 
and 1 M NaCl.  R A indicates the amount of ligand captured (880RU), R B 
indicates the final surface following L-cysteine capture. 
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Figure 4. Comparison of subtracted sensorgram obtained after the injections of a 
series of pUC19 concentration over the 16mer peptide surface and blank surface with 
a 600.1 g/ml control plasmid pEGFP-N1. The increase in response unit was 
observed after pUC19 loading while no change with pEGFP – N1 loading. 
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Figure 5. Adsorption isotherm for plasmid pUC19 binding to 16mer peptide 
immobilized to a Biacore C1 chip measured in response units. The C1 chip was 
equilibrated before each run with HBS buffer and regenerated after each run. The 
amount of bound plasmid DNA was estimated by monitoring the surface plasmon 
resonance signal (RU) at a fixed time just before the end of injection. Rmax/2 = KD, 
so the dissociation constant of the binding between pDNA and 16mer peptide was  
0.5 × 10–7 M = 5 × 10–8 M. 
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Figure 6. Chromatogram of plasmid pUC19 loaded on 16mer peptide immobilised on 
self-made monolith. Bound plasmid DNA was eluted using PBS buffer (0.01 M PBS, 
KCl 0.0027M; pH7.4) with additional NaCl (final concentration: 1M). Inset image: 
0.8 % Ethidium Bromide agarose electrophoresis gel of purified plasmid DNA.  Lane 
1: pDNA sample 5µl, lane M: 5µl 25µg/ml 1kbp DNA ladder. The clear apparent 
band is supercoiled (SC) pDNA. 
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Figure 7a. Agarose electrophoresis gel of plasmid DNA with 16mer peptide 
immobilised on a 4 ml customized monolith (negative agarose gel). M: 1kb DNA 
marker; lanes 1 and 2: eluted pDNA; Figure 7b. Restriction endonuclease digestion 
of purified pDNA. EcoRI cut supercoiled pDNA into linear pDNA (ca. 3kbp) using 
the method described before[54]. 
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Figure 8. Breakthrough curve of plasmid DNA using 16mer peptide – monolith 
chromatography.69.9 µg/ml of plasmid in 0.01M PBS buffer was loaded in the 
breakthrough experiment. 
 
 
